RCUS Arcus Biosciences, Inc.
Healthcare$24.13+2.99%ClosedMarket Cap: $2.43B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.61
P/S
9.99
EV/EBITDA
-6.66
DCF Value
$-37.12
FCF Yield
-20.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.0%
Operating Margin
-168.6%
Net Margin
-156.4%
ROE
-69.0%
ROA
-37.0%
ROIC
-50.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $17.0M | 88.2% | $-134.0M | $-128.0M | $— | — |
| Q4 null | $33.0M | 90.9% | $-114.0M | $-98.0M | $— | — |
| FY null | $247.0M | 96.0% | $-386.0M | $-353.0M | $— | — |
| Q3 null | $26.0M | 92.3% | $-142.0M | $-135.0M | $— | — |
| Q2 null | $160.0M | 100.0% | $-8.0M | $-8.0M | $— | — |
| Q1 null | $28.0M | 100.0% | $-122.0M | $-112.0M | $— | — |
| Q4 null | $26.0M | 100.0% | $-103.0M | $-94.0M | $— | — |
| FY null | $258.0M | 100.0% | $-330.0M | $-283.0M | $— | — |
| Q3 null | $48.0M | 100.0% | $-105.0M | $-92.0M | $— | — |
| Q2 null | $39.0M | 100.0% | $-106.0M | $-93.0M | $— | — |
| Q1 null | $145.0M | 100.0% | $-16.0M | $-4.0M | $— | — |
| Q4 2023 | $31.0M | 100.0% | $-91.0M | $-81.0M | $-1.08 | — |